Supplementary Table 1 - FON-2021-1406 - INSIGHT 2: A Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance

Table S1. Clinical outcomes with first-, second- and third-generation EGFR TKIs received as first-line therapy in randomized controlled clinical trials of EGFR TKIs in EGFR-mutant advanced NSCLC [1–22] EGFR: epidermal growth factor receptor; NSCLC: non-small cell lung cancer; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; TKI: tyrosine kinase inhibitor. INSIGHT 2: A Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance